pharmaphorum

MARCH 15, 2021

Novartis has said its gene therapy pricing model, involving a steep one-off payment, could be a template for the hundreds of similar treatments that could follow its Zolgensma for Spinal Muscular Atrophy (SMA). . There are around 350 gene therapies in various studies.”. The post Novartis says £1.8m

Gene Therapy 96

Gene Therapy Gene Pharma Companies Clinical Trials 96

Bio Pharma Dive

JULY 22, 2022

The pharma company plans to spend $70 million on the South San Francisco facility, which will house West Coast employees of Astellas Gene Therapies.

Gene Therapy 143

Gene Therapy Pharma Companies Gene Research 143

Pharma Times

JUNE 10, 2021

German pharma company announces progress in its 'two-pronged' cell and gene therapy approach to Parkinson's disease

Gene Therapy 121

Gene Therapy Pharma Companies Gene 121

pharmaphorum

NOVEMBER 23, 2022

uniQure and CSL have become the first pharma companies to get regulatory approval for a gene therapy for haemophilia B anywhere in the world, after the FDA cleared their Hemgenix therapy for adults with the bleeding disorder in the US.

Gene Therapy 59

Gene Therapy Gene FDA Approval Trials 59

BioPharma Reporter

OCTOBER 31, 2023

The London and New York-based gene therapy player MeiraGTx Holdings has received a $30 million investment from Sanofi in addition to potential strategic deals with the big pharma company down the road.

Gene Therapy 52

Gene Therapy Gene Pharma Companies Regulation 52

pharmaphorum

NOVEMBER 12, 2020

UCB has made a new foray into the gene therapy space, buying fellow Belgium-based company Handl to get control of its adeno-associated virus (AAV) capsid delivery platform and two research programmes in neurodegenerative diseases. The post UCB revs up its gene therapy drive with Handl acquisition appeared first on.

Gene Therapy 52

Gene Therapy Gene Manufacturing Contract Manufacturing 52

Cloudbyz

MAY 19, 2021

Introduction Cell and gene therapy is an upcoming wave of therapeutic innovation in the healthcare and life sciences industry and is being pragmatically accepted worldwide. The gene therapy market reported its first market approvals back in 2017 and the evolution has been extensive ever since.

Gene Therapy 52

Gene Therapy Gene Manufacturing Production 52

pharmaphorum

NOVEMBER 30, 2020

Cure Rare Disease’s Rich Horgan discusses the importance of preclinical NAbs screening and helping rare disease patients better understand their eligibility for gene therapies. In serious cases, higher levels of pre-existing NAbs can even cause a dangerous immune reaction when such therapies are administered.

Gene Therapy 105

Gene Therapy Gene Antibody Clinical Trials 105

XTalks

DECEMBER 27, 2022

Adstiladrin is an adenoviral vector-based gene therapy that is non-replicating, so it cannot multiply in human cells. The pharma company will expand its manufacturing capacity for commercial scale vector production for oncology treatment. How Does the Gene Therapy Adstiladrin Work?

Gene Therapy 52

Gene Therapy FDA Approval Gene Clinical Trials 52

Fierce Pharma

MARCH 21, 2024

Three large pharma companies plan to expand their manufacturing footprints. million gene therapy set a new world pricing record. Three large pharma companies plan to expand their manufacturing footprints. million gene therapy set a new world pricing record. Kyowa Kirin’s $4.25 Kyowa Kirin’s $4.25

Gene Therapy 72

Gene Therapy Pharma Companies Gene Manufacturing 72

Pharmaceutical Technology

JULY 6, 2022

This period of hype saw companies going public earlier, which could explain why we may see some companies being merged or bought out, says Jason Foster, CEO of Ori Biotech, a private cell and gene therapy manufacturing company.

Marketing 324

Marketing Gene Therapy Manufacturing Pharma Companies 324

pharmaphorum

MAY 21, 2021

This is especially relevant for the new era of gene therapies that are disease modifying, offering hope for some of the most intractable and devastating diseases, many of which affect children. How can we ensure pharma companies continue to innovate if there are these hurdles?

Gene Therapy 119

Gene Therapy Gene Clinical Trials Clinical Trials 119

XTalks

JANUARY 4, 2023

With a handful of significant gene therapy approvals in 2022, the cell and gene therapy space continues to rapidly expand, and hence we can expect more ground-breaking gene therapy approvals in the coming year, particularly for rare diseases. Read the full article here: 4 Life Sciences Trends for 2023.

Life Science 52

Life Science Gene Therapy Gene Pharma Companies 52

pharmaphorum

DECEMBER 14, 2022

Last month we saw some movement in the pharma world, but also in some of the orbiting worlds of agencies, consultancies, and pharma investors. In addition, two team members are taking on new roles at the company, with Glen Webster named EVP of global operations and Jennifer White named global head of growth. New CEO joins UBC.

Life Science 98

Life Science Gene Therapy Gene Editing Gene 98

Pharmaceutical Technology

JUNE 14, 2023

Future waves of approvals for ATMPs (advanced therapy medicinal products, e.g., cell and gene therapies) will heighten demand on the contract packaging industry, further increasing the need for advanced cold chain solutions and specialized packaging designed to withstand cryogenic temperatures.

Contract Packaging 130

Contract Packaging Packaging Packaging Development 130

pharmaphorum

SEPTEMBER 29, 2020

As of 2018, there were over 1,100 cancer therapies in development, and as of 2020, 362 of them were cell and gene therapies. Many novel therapies have been successfully developed through such partnerships. Case Study: From Technology Agreement to co-development and co-commercialisation partnership.

Research 132

Research Gene Editing Development Gene 132

Pharmaceutical Technology

JULY 6, 2022

This period of hype saw companies going public earlier, which could explain why we may see some companies being merged or bought out, says Jason Foster, CEO of Ori Biotech, a private cell and gene therapy manufacturing company. Ori raised over $100 million (EUR97.52

Marketing 162

Marketing Gene Therapy Manufacturing Pharma Companies 162

Pharmaceutical Technology

MAY 26, 2023

Pharma company merger and acquisition (M&A) activity in the first half of 2023 has remained relatively low, consistent with the second half of last year, but investors predict deals will increase later in 2023. Experts at PWC, Goldman Sachs, and Morgan Stanley agree that pharma-related M&A is expected to pick up in 2023.

Life Science 130

Life Science Manufacturing Contract Manufacturing Gene Therapy 130

pharmaphorum

APRIL 21, 2022

One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson’s disease – AbbVie – is ducking out of the challenge. Then, in January, Sanofi stumped up $75 million upfront for a preclinical-stage bispecific antibody from South Korea’s ABL Bio in a $1 billion deal.

Antibody 97

Antibody Protein Gene Therapy Pharma Companies 97

XTalks

DECEMBER 20, 2023

“In 2024, pharma companies and emerging biotechs will improve candidate safety profiles and reduce off-target effects by exploiting predictive intelligence unlocked by AI,” she predicts. CRISPR Gene Editing Therapeutics CRISPR/Cas-9 technology makes lists like this almost every year, and for good reason.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

pharmaphorum

AUGUST 4, 2021

This changed with the 2017 release of Biogen’s Spinraza, the first FDA-approved therapy for SMA. The drug – the first of a new generation of gene therapies – has been demonstrated to significantly impact disease progression. About the author.

Gene Therapy 145

Gene Therapy FDA Approval Pharma Companies Development 145

Pharmaceutical Technology

JANUARY 31, 2023

While insulin price caps will begin this year, larger effects will be delayed until 2026 – when the US federal government will be allowed to negotiate Medicare prices and demand rebates from drug companies that price gouge. That leaves three years for pharma companies to prepare. It’s much needed. It’s a hot area.”

Drugs 130

Drugs Gene Therapy Regulation Insulin 130

pharmaphorum

MARCH 22, 2022

The efforts underway to strengthen the manufacturing process across the industry have become more important than ever, as the therapies the industry is developing increase in complexity. However, with a number of deals and investments being made in the space, the demand is there to develop more efficient methods of training and manufacturing.

Manufacturing 137

Manufacturing Production Contamination Gene Therapy 137

pharmaphorum

SEPTEMBER 22, 2022

Companies can only do so much to market digital therapeutics until certain information infrastructure is in place, says Kristin Milburn, managing director of Healthware Labs. Gene therapies for prevalent diseases in Europe. Moving forward the evolution of digital maturity in pharma. Frontiers Health 2022.

Gene Therapy 52

Gene Therapy Marketing Gene Sales 52

pharmaphorum

SEPTEMBER 17, 2021

Havas Life Medicom, ARK and Pharmadoctor top the agency charts AstraZeneca, klarify and Novartis Gene Therapies top the pharma leader board. Among pharma companies and healthcare organisations, the top three companies, taking two Golds each, were AstraZeneca, klarify and Novartis Gene Therapies.

Gene Therapy 52

Gene Therapy Gene Allergies Life Science 52

pharmaphorum

JANUARY 24, 2023

Pharma has used this to begin creating targeted treatments, such as gene therapies , which are able to hone in on gene mutations that cause health issues and eradicate or replace the faulty gene.

Genetics 98

Genetics Drugs Genome Project Biobanking 98

pharmaphorum

NOVEMBER 30, 2022

The biggest gathering of pharma companies in Europe right now on the commercial side, the Veeva Systems Summit permits the sharing of best practices and of new ideas. Facts that they gleaned included: Across Europe, only 52% of HCPs will accept a visit from a pharma company (i.e.

Life Science 98

Life Science Pharma Companies Sales Marketing 98

pharmaphorum

NOVEMBER 22, 2022

Francis, who is currently CEO of gene therapy specialist Purespring Therapeutics and cardiovascular drug developer company Forcefield Therapeutics, is due to take the top job at Teva on 1 January, and will serve as the pharma company’s president. Richard Francis.

Sales 59

Sales Gene Therapy Pharma Companies Gene 59

The Pharma Data

JANUARY 24, 2021

.–( BUSINESS WIRE )– Faze Medicines , a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Philip Vickers, Ph.D., Preclinical and clinical programs at Northern Biologics were acquired by big pharma companies in 2020.

Medicine 52

Medicine Pharma Companies Gene Therapy Development 52

pharmaphorum

DECEMBER 1, 2022

Learn how to implement 3D Cell Culture techniques for antibody and cell and gene therapy discovery process. Utilise 3D cell culture for personalised drug screening and high-throughput screening over traditional 2D methods. Delve into advanced case studies looking into organ models: from the blood-brain barrier to liver spheroids.

In-Vitro 52

In-Vitro Scientist Engineer Gene Therapy 52

pharmaphorum

SEPTEMBER 11, 2019

The advent of highly novel cell and gene therapies as well as prescription digital therapeutics is providing a serious set of forces for change in the market. Another comes from the challenges developed markets face, which renews the urgency for pharma companies to spread their launch successes beyond traditionally core markets.

Gene Therapy 40

Gene Therapy Pharma Companies Marketing Gene 40

pharmaphorum

APRIL 28, 2022

Although they have, by definition, small addressable markets, the treatments cost just as many resources to develop as therapies for more common diseases – sometimes more, because of the added difficulty of finding sufficiently large patient populations for trials and finding disease experts to run them. How big pharma tackles rare diseases.

Pharma Companies 59

Pharma Companies Branding Development Marketing 59

Delveinsight

JULY 26, 2020

However, pharma companies such as TauRx Therapeutics , Axon Neuroscience SE , Prevail Therapeutics , Avid Radiopharmaceuticals , and Alector are actively working to buildup the Frontotemporal dementia pipeline. The Frontotemporal dementia market is expected to increase with a CAGR of 21.41% for 7MM during the study period.

Marketing 54

Marketing Pharma Companies Manufacturing Clinical Trials 54

Pharma Marketing Network

FEBRUARY 27, 2025

So, how can pharma companies use content marketing to engage HCPs and patients effectively ? Pharma brands can develop: Whitepapers on clinical trials showcasing drug effectiveness. Publish thought leadership articles on digital health, AI in pharma, or precision medicine. Lets dive in.

Branding 52

Branding Marketing Compliance Pharma Companies 52

Drug Channels

FEBRUARY 6, 2024

PAP – Patient Assistance & Access Programs Download Agenda | See Who’s Speaking The experts will be taking the most pressing challenges industry is facing head on, including: Emerging Policy Changes and Enforcement Actions The Impact of AFPs on PAPs Program Automation for Operational Efficiency Ensuring Health Equity Where It Matters Most Patient (..)

Pharmacy 40

Pharmacy Gene Therapy Pharma Companies Production 40

The Pharma Data

DECEMBER 17, 2020

Smith joined SpringWorks at the company’s inception in 2017 and was a founding member of the management team. Prior to SpringWorks, Smith was the executive vice president of Gene Therapy at Bamboo Therapeutics. AB2 Bio – Swiss pharma company AB2 Bio Ltd. named Djordje Filipovic as its new chief commercial officer.

Development 52

Development Gene Therapy Engineer Life Science 52

WCG Clinical

JUNE 4, 2024

We started, you know, experimenting with different gene therapies and antisense therapies. And the the truth is that even in these smaller rare diseases that are single gene mutations, mutation, is it a missense? Our foundation has, we have identified a lead gene therapy candidate. Is it a nonsense?

Research 52

Research Clinical Trials Clinical Trials Doctors 52